Skip to content
Advertisement

FILE - This July 2019 image provided by the Sarah Cannon Research Institute shows Victoria Gray on her infusion day during a gene editing trial for sickle cell disease at the Sarah Cannon Research Institute and The Children's Hospital At TriStar Centennial in Nashville. Gray, the first patient to test the treatment, shared her experience with researchers at a scientific conference in 2023. She described suffering with terrible bouts of pain since childhood and receiving high-dose pain medications and sometimes blood transfusions. She described feeling she "was being reborn” the day she got the gene therapy. (Anthem Pictures/Sarah Cannon Research Institute via AP, File)

FILE - This July 2019 image provided by the Sarah Cannon Research Institute shows Victoria Gray on her infusion day during a gene editing trial for sickle cell disease at the Sarah Cannon Research Institute and The Children's Hospital At TriStar Centennial in Nashville. Gray, the first patient to test the treatment, shared her experience with researchers at a scientific conference in 2023. She described suffering with terrible bouts of pain since childhood and receiving high-dose pain medications and sometimes blood transfusions. She described feeling she "was being reborn” the day she got the gene therapy. (Anthem Pictures/Sarah Cannon Research Institute via AP, File)

Featured Photo Galleries